College of Health Science, Debre Markos University, Debre Marko, Ethiopia.
Debre Markos Referral Hospital, Debre Marko, Ethiopia.
PLoS One. 2019 May 1;14(5):e0215300. doi: 10.1371/journal.pone.0215300. eCollection 2019.
BACKGROUND: Human immunodeficiency virus (HIV) infection is a major public health concern globally, especially in sub-Saharan African countries. Even though determining the incidence of treatment failure and its predictor is a crucial step to reduce the problem, there is limited information indicating the incidence and predictors of treatment failure among children in Ethiopia. Therefore, this study was conducted to assess the incidence and predictors of treatment failure among children on first-line antiretroviral therapy (ART) in Amhara Region referral hospitals, Northwest Ethiopia. METHODS: An institution-based retrospective follow-up study was conducted from January 30, 2011, to January 30, 2018. A total of 402 children on first-line antiretroviral therapy were selected with a simple random sampling method in Amhara Region Referral Hospitals, Northwest Ethiopia. Data were extracted by reviewing patients' ART intake and follow-up forms using pretested and structured checklists. The collected data were entered into Epidata Version 4.2 and analysis was done using STATA Version 13. Bivariable and multivariable Cox proportional hazards regression models were fitted to identify predictors of treatment failure. RESULTS: A total of 402 records of children on antiretroviral therapy (ART) were reviewed and treatment failures rate within the follow-up period were 12.19% (95% CI: 8.5, 15.88). This study also found that the overall incidence density rate was 3.77% per 100 person-years observation. Virologic failure accounts 48.98% followed by immunologic (28.57%) and mixed failures (22.44%). Poor ART adherence (AHR: 4.6, 95%CI: 1.61, 13.20), drug regimens, AZT-3TC-NVP (AHR: 5.2, 95%CI: 1.9, 14.26), and AZT-3TC-EFV (AHR: 6.26, 95% CI: 1.88, 20.87), Children whose both parent were died (AHR: 2.8, 95%CI: 1.07, 7.37) and world health organization (WHO) clinical stage-4 (AHR: 2.95, 95%CI: 1.04, 8.366) were found to be predictors for treatment failure among children. CONCLUSION: The proportion of treatment failure among children on first-line ART in Amhara Region referral hospitals, Northwest Ethiopia was found to be high. Nearly half of the children experienced Virologic failure. Poor ART adherence, children whose parents`died without parents, WHO clinical stage-4 at baseline and type of regimen patients took were found to be predictors of first-line ART treatment failure. Therefore, expanding access to routine viral load, CD4 and clinical monitoring is mandatory to detect and early intervene of treatment failures' to improve outcomes for children on ART. Patient caregivers or parents should strictly support children on medication adherence. Training to health professionals should be given time-based on revised guidelines, and follow up of treatment outcome should be monitored nationally to take the appropriate intervention.
背景:人类免疫缺陷病毒(HIV)感染是一个全球性的主要公共卫生问题,特别是在撒哈拉以南非洲国家。尽管确定治疗失败的发生率及其预测因素是减少该问题的关键步骤,但关于埃塞俄比亚儿童治疗失败的发生率和预测因素的信息有限。因此,本研究旨在评估在埃塞俄比亚阿姆哈拉地区转诊医院接受一线抗逆转录病毒治疗(ART)的儿童中治疗失败的发生率和预测因素。
方法:这是一项 2011 年 1 月 30 日至 2018 年 1 月 30 日期间在阿姆哈拉地区转诊医院进行的基于机构的回顾性随访研究。采用简单随机抽样法从阿姆哈拉地区转诊医院选择了 402 名接受一线抗逆转录病毒治疗的儿童。通过审查患者的 ART 摄入量和随访表,使用经过预测试和结构化检查表提取数据。收集的数据输入到 EpiData 版本 4.2 中,并使用 STATA 版本 13 进行分析。采用单变量和多变量 Cox 比例风险回归模型来确定治疗失败的预测因素。
结果:共回顾了 402 份接受抗逆转录病毒治疗(ART)的儿童记录,在随访期间治疗失败率为 12.19%(95%CI:8.5,15.88)。本研究还发现,总体发生率密度为每 100 人年观察 3.77%。病毒学失败占 48.98%,其次是免疫学(28.57%)和混合失败(22.44%)。ART 依从性差(AHR:4.6,95%CI:1.61,13.20)、药物方案、AZT-3TC-NVP(AHR:5.2,95%CI:1.9,14.26)和 AZT-3TC-EFV(AHR:6.26,95%CI:1.88,20.87)、父母双亡的儿童(AHR:2.8,95%CI:1.07,7.37)和世界卫生组织(WHO)临床分期 4 期(AHR:2.95,95%CI:1.04,8.366)被发现是儿童治疗失败的预测因素。
结论:在阿姆哈拉地区转诊医院接受一线 ART 治疗的儿童中,治疗失败的比例很高。近一半的儿童出现病毒学失败。ART 依从性差、父母双亡的儿童、基线时的 WHO 临床分期 4 期以及患者接受的治疗方案是一线 ART 治疗失败的预测因素。因此,扩大常规病毒载量、CD4 和临床监测的获取是发现和早期干预治疗失败以改善接受 ART 治疗的儿童结果所必需的。患者护理人员或父母应严格支持儿童服药依从性。应根据修订后的指南定期为卫生专业人员提供培训,并在全国范围内监测治疗结果,以采取适当的干预措施。
BMC Infect Dis. 2016-2-3
S Afr Med J. 2014-6-26